Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 453 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR Looking back at a life-changing clinical trial September 16, 2022 We have a Deal: What does the new UK-EU relationship mean... January 4, 2021 Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press... September 20, 2020 Load more HOT NEWS Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations
